Growing cancer rate in India: A reality check
Healthcare Radius
|March 2023
An analysis of the underlying causes of the rising cancer rate in India and the potential solutions to control its spread
It is an undeniable fact that cancer prevention thrives on its early detection. Despite the therapeutic and technological advancement, 80 percent of cancers in low-and-middle-income countries are invariably detected at an advanced stage. Although a majority of cancer cases are detected in the age group of 45 to 60, we do find a growing (albeit not alarming as yet) incidence of breast cancer, nasopharyngeal cancer, and hematological malignancies in the age group of 20 to 40. In recent times, we are also seeing more cases of ovarian cancer in this age group.
There have been a lot of studies worldwide on this phenomenon. In this context, it is pertinent to note that the analysis done by HCG revealed that the mortality in the 16-40 age group was 14 percent, and the mortality in the 40 to 60 age group was 60 percent.
The analysis also revealed that the proportion of mortality was the highest in Bone and Soft tissue sarcoma cases in this age group. Notwithstanding the small proportion compared to adult populations, the current scenario is indeed a cause of concern.
The causes of the rise
So, why are we seeing a rise in cancer cases across all age groups? One school of thought says cancer was always prevalent, but as cancer detection was poor before, more cases are being reported in recent times. There is a fractional element of truth in that conjecture - given better community awareness, improving access to healthcare, and the pivotal role played by technological innovations that we see today - but it is not the principal reason for the rising number of cancer cases.
Bu hikaye Healthcare Radius dergisinin March 2023 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Healthcare Radius'den DAHA FAZLA HİKAYE
Healthcare Radius
VENUS REMEDIES GETS DRUG APPROVALS IN VIETNAM
Venus Remedies, a fixed-dosage injectable manufacturer, has secured new marketing authorisations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam.
1 mins
December 2025
Healthcare Radius
A HEALTHIER INDIA IN THE MAKING: LEADERS DECODE THE ROAD FROM 2025 TO 2026
The collective goal is clear and unanimous: to transition from a system that primarily treats sickness to one that actively promotes lifelong health and well-being.
12 mins
December 2025
Healthcare Radius
FROM GENES TO CARE: ADVANCING CLINICAL UNDERSTANDING OF HYPOPHOSPHATASIA
From genes to care, the story of hypophosphatasia reminds us that progress in medicine isn't only about scientific discovery, it's about turning knowledge into healing.
6 mins
December 2025
Healthcare Radius
ALEMBIC PHARMA GETS USFDA NOD FOR DILTIAZEM TABLETS IN THE US
Alembic Pharmaceuticals (Alembic) Aamour announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg.
1 min
December 2025
Healthcare Radius
ZYDUS GETS USFDA APPROVAL FOR PROSTATE CANCER INJECTABLE
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).
1 min
December 2025
Healthcare Radius
SUPERHEALTH LAUNCHES HONEST SECOND OPINION FOR PATIENTS
Superhealth, a zero-wait, commission Superhealth, zerohospital network, announced the launch of \"Honest Second Opinion,\" a service that helps patients make informed decisions about their treatment plans and surgical recommendations.
1 min
December 2025
Healthcare Radius
KOTAK ALTS INVESTS RS 400MN IN MEDIVERSAL
Kotak Alternate Asset Managers (Kotak Alts), through its Kotak Life Science Fund I, which invests in early to growth-stage life sciences and healthcare businesses, has made an investment of Rs 400 million in Mediversal Healthcare.
1 min
December 2025
Healthcare Radius
INVIGA HEALTHCARE FUND ACQUIRES 21% STAKE IN FORUS HEALTH
Inviga Healthcare Fund (IHF), the private equity platform founded by Dr B. S. Ajaikumar of HCG, has acquired a 21 per cent stake in Forus Health, an ophthalmic diagnostics company whose devices have screened over 22 million patients across 75+ countries.
1 min
December 2025
Healthcare Radius
OPTIMISING MATERNITY OPS: REDUCING C-SECTION BURDEN THROUGH EVIDENCE-BASED PROTOCOLS
By building systems that support safety, documentation, and respectful care, institutions can improve outcomes, lower litigation risks, and strengthen quality scores, achieving what healthcare should truly represent: Care Through Trust.”
7 mins
December 2025
Healthcare Radius
MENTAL HEALTH CARE GOES DIGITAL WITH NEW THERAPY PLATFORM
Following the global observance and continuing the commitment to mental well-being, renowned clinical psychologist Kanika Jindal announced the launch of Harmony Therapy World, a holistic digital platform designed to bring emotional healing and psychological support to people everywhere, privately, compassionately, and without barriers.
1 min
December 2025
Translate
Change font size
